Literature DB >> 8160235

Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats.

M Chopp1, R L Zhang, H Chen, Y Li, N Jiang, J R Rusche.   

Abstract

BACKGROUND AND
PURPOSE: Postischemic cerebral inflammation may contribute to ischemic cell damage. The CD11b/18 (Mac-1) integrin mediates stimulated neutrophil binding to endothelia. We therefore investigated the effect of administration of an anti-Mac-1 monoclonal antibody on cerebral ischemic cell damage in the rat.
METHODS: Rats (n = 10) were subjected to 2 hours of middle cerebral artery occlusion; the anti-Mac-1 antibody was administered at a dose of 2 mg/kg i.v. at 1 hour of reperfusion and 1 mg/kg i.v. at 22 hours of reperfusion or an isotype-matched control antibody (n = 10) was administered using the same experimental protocol. Rats were killed at 46 hours of reperfusion, and brain sections were stained with hematoxylin and eosin for histological evaluation. In a separate population of rats given either vehicle (n = 8) or anti-Mac-1 antibodies (n = 9), intraparenchymal neutrophils were measured by means of a myeloperoxidase assay.
RESULTS: The lesion volume was significantly smaller (28%) in the anti-Mac-1 antibody group compared with the vehicle control group (P < .01). Numbers of intraparenchymal polymorphonuclear cells were significantly reduced (P < .05) in the cortex of the anti-Mac-1 antibody group compared with the vehicle control group.
CONCLUSIONS: Our data demonstrate that administration of anti-Mac-1 antibody 1 hour after onset of reperfusion results in significant reductions of ischemic cell damage and intraparenchymal neutrophils after transient (2-hour) focal cerebral ischemia in the rat.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160235     DOI: 10.1161/01.str.25.4.869

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  46 in total

1.  Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?

Authors:  C J Vaughan; N Delanty; C T Basson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Pharmacologic neuroprotection: the search continues.

Authors:  Hilary P Grocott
Journal:  J Extra Corpor Technol       Date:  2007-12

Review 3.  Neuroprotection during cardiac surgery.

Authors:  Hilary P Grocott; Kenji Yoshitani
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

Review 4.  Inflammatory mechanisms in ischemic stroke: role of inflammatory cells.

Authors:  Rong Jin; Guojun Yang; Guohong Li
Journal:  J Leukoc Biol       Date:  2010-02-03       Impact factor: 4.962

Review 5.  Role of proinflammatory cytokines in cerebral ischemia: a review.

Authors:  B K Sharma; K Kumar
Journal:  Metab Brain Dis       Date:  1998-03       Impact factor: 3.584

6.  Slit modulates cerebrovascular inflammation and mediates neuroprotection against global cerebral ischemia.

Authors:  Tamer Altay; Bethann McLaughlin; Jane Y Wu; T S Park; Jeffrey M Gidday
Journal:  Exp Neurol       Date:  2007-07-26       Impact factor: 5.330

7.  The spleen contributes to stroke-induced neurodegeneration.

Authors:  Craig T Ajmo; Dionne O L Vernon; Lisa Collier; Aaron A Hall; Svitlana Garbuzova-Davis; Alison Willing; Keith R Pennypacker
Journal:  J Neurosci Res       Date:  2008-08-01       Impact factor: 4.164

Review 8.  [Statins for treatment of CNS diseases. Status report from research and clinical practice].

Authors:  T Menge; H-C von Büdingen; S S Zamvil; H-P Hartung; B C Kieseier; O Stüve
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

9.  Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils.

Authors:  S Satoh; I Ikegaki; Y Suzuki; T Asano; M Shibuya; H Hidaka
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 10.  Cell adhesion molecules and ischemic stroke.

Authors:  Gokhan Yilmaz; D Neil Granger
Journal:  Neurol Res       Date:  2008-10       Impact factor: 2.448

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.